Critical Reviews in Oncology / Hematology
Volume 74, Issue 2 , Pages 134-148 , May 2010

Major and minor salivary gland tumors

  • Marco Guzzo

      Affiliations

    • Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy
    • ,
  • Laura D. Locati

      Affiliations

    • Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy
    • ,
  • Franz J. Prott

      Affiliations

    • Radiotherapy, Wiesbaden, Germany
    • ,
  • Gemma Gatta

      Affiliations

    • Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy
    • ,
  • Mark McGurk

      Affiliations

    • Guy's and St. Thomas’ Hospital Trust, London, UK
    • ,
  • Lisa Licitra

      Affiliations

    • Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy
    • Corresponding Author InformationCorresponding author at: Head and Neck Medical Oncology Unit, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Via Venezian 1, 20133 Milano, Italy. Tel.: +39 02 23903352; fax: +39 02 23903353.

,Accepted 20 October 2009.

References 

  1. WHO, World Health Organization. International statistical classification of diseases and related health problems, tenth revision, vol. 1. Geneva; 1992.
  2. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents, vol. VIII. IARC Scientific Publications No. 155. Lyon: IARC Press; 2002.
  3. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 2005;114:806–816
  4. Berrino F, De AR, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–1999: results of the EUROCARE-4 study. Lancet Oncol. 2007;8:773–783
  5. Horn-Ross PL, Morrow M, Ljung BM. Diet and the risk of salivary gland cancer. Am J Epidemiol. 1997;146:171–176
  6. Zheng W, Shu XO, Ji BT, Gao YT. Diet and other risk factors for cancer of the salivary glands: a population-based case–control study. Int J Cancer. 1996;67:194–198
  7. Schneider AB, Lubin J, Ron E, et al. Salivary gland tumors after childhood radiation treatment for benign conditions of the head and neck: dose–response relationships. Radiat Res. 1998;149:625–630
  8. Coleman MP, Babb P, Daniecki P, et al. Cancer survival trends in England and Wales, 1971–1995: deprivation and NHS region. Studies in medical and population subjects no. 61. London: The Stationary Office. 1999.
  9. Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958–1996: a search for common mechanisms. Br J Cancer. 2001;85:997–1005
  10. Goldstein AM, Yuen J, Tucker MA. Second cancers after medulloblastoma: population-based results from the United States and Sweden. Cancer Causes Control. 1997;8:865–871
  11. Milan T, Pukkala E, Verkasalo PK, et al. Subsequent primary cancers after basal-cell carcinoma: a nationwide study in Finland from 1953 to 1995. Int J Cancer. 2000;87:283–288
  12. Spitz MR, Tilley BC, Batsakis JG, Gibeau JM, Newell GR. Risk factors for major salivary gland carcinoma. A case–comparison study. Cancer. 1984;54:1854–1859
  13. Serraino D, Boschini A, Carrieri P, et al. Cancer risk among men with, or at risk of HIV infection in southern Europe. AIDS. 2000;14:553–559
  14. Horn-Ross PL, Ljung BM, Morrow M. Environmental factors and the risk of salivary gland cancer. Epidemiology. 1997;8:414–419
  15. Swanson GM, Burns PB. Cancers of the salivary gland: workplace risks among women and men. Ann Epidemiol. 1997;7:369–374
  16. Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005;p. 254–8
  17. Locati LD, Losa M, Perrone F, et al. C252 treatment relevant immunophenotyping of 139 Salivary Gland Carcinoma (SGCs). In: AACR-NCI-EORTC international conference on molecular targets and cancer therapeuticc. Philadelphia, PA, USA. 2005;
  18. Dahse R, Driemel O, Schwarz S, et al. Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. Br J Cancer. 2009;100:623–625
  19. Locati LD, Bossi P, Lo Vullo S, et al. Prognostic role of epidermal growth factor receptors 1 & 2, androgen receptor and kit in 111 salivary gland cancer. In: 7th international conference on head & neck cancer. 2008;p. S067
  20. Ettl T, Schwarz S, Kleinsasser N, et al. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology. 2008;53:567–577
  21. Skalova A, Starek I, Vanecek T, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology. 2003;42:348–356
  22. Dagrada GP, Negri T, Tamborini E, Pierotti MA, Pilotti S. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology. 2004;44:301–302
  23. Press MF, Pike MC, Hung G, et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 1994;54:5675–5682
  24. Andreadis D, Epivatianos A, Poulopoulos A, et al. Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol. 2006;42:57–65
  25. Chandan VS, Wilbur D, Faquin WC, Khurana KK. Is c-kit (CD117) immunolocalization in cell block preparations useful in the differentiation of adenoid cystic carcinoma from pleomorphic adenoma?. Cancer. 2004;102:207–209
  26. Holst VA, Marshall CE, Moskaluk CA, Frierson HF. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol. 1999;12:956–960
  27. Jeng YM, Lin CY, Hsu HC. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett. 2000;154:107–111
  28. Sorensen KB, Godballe C, de SK, Krogdahl A. Parotid carcinoma: expression of kit protein and epidermal growth factor receptor. J Oral Pathol Med. 2006;35:286–291
  29. Glas AS, Hollema H, Nap RE, Plukker JT. Expression of estrogen receptor, progesterone receptor, and insulin-like growth factor receptor-1 and of MIB-1 in patients with recurrent pleomorphic adenoma of the parotid gland. Cancer. 2002;94:2211–2216
  30. Penner CR, Folpe AL, Budnick SD. C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod Pathol. 2002;15:687–691
  31. Edwards PC, Bhuiya T, Kelsch RD. C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95:586–593
  32. Vered M, Braunstein E, Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck. 2002;24:632–636
  33. Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004;10:944–946
  34. Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol. 2003;119:801–806
  35. Moriki T, Ueta S, Takahashi T, Mitani M, Ichien M. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer. 2001;93:344–350
  36. Andersen LJ, Therkildsen MH, Ockelmann HH, et al. Malignant epithelial tumors in the minor salivary glands, the submandibular gland, and the sublingual gland. Prognostic factors and treatment results. Cancer. 1991;68:2431–2437
  37. In:  Ellis GL,  Auclair PL editor. Tumors of the salivary glands. AFIP atlas of tumor pathology, 4th series, fascicle 9. Silver Spring, MD: ARP Press; 2008;
  38. Hocwald E, Yoo GH, Adsay V, et al. Prognostic factors in major salivary gland cancer. Laryngoscope. 2001;111:1434–1439
  39. Lima RA, Tavares MR, Dias FL, et al. Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol Head Neck Surg. 2005;133:702–708
  40. In:  Batsakis JG editors. Tumours of the head and neck. Clinical and pathological considerations. 2nd ed.. Baltimore/London: Williams & Wilkins; 1982;
  41. Waldron CA, el-Mofty SK, Gnepp DR. Tumors of the intraoral minor salivary glands: a demographic and histologic study of 426 cases. Oral Surg Oral Med Oral Pathol. 1988;66:323–333
  42. Lopes MA, Kowalski LP, da Cunha SG, Paes de AO. A clinicopathologic study of 196 intraoral minor salivary gland tumours. J Oral Pathol Med. 1999;28:264–267
  43. Kress E, Schulz HG, Neumann T. Diagnosis of diseases of the large salivary glands of the head by ultrasound, sialography and CT-sialography: a comparison of methods. HNO. 1993;345–351[German]
  44. Kurabayashi T, Ida M, Ohbayashi N, Ishii J, Sasaki T. Criteria for differentiating superficial from deep lobe tumours of the parotid gland by computed tomography. Dentomaxillofac Radiol. 1993;22:81–85
  45. Traxler M, Schurawitzki H, Ulm C, et al. Sonography of nonneoplastic disorders of the salivary glands. Int J Oral Maxillofac Surg. 1992;21:360–363
  46. Spiro RH. Changing trends in the management of salivary tumors. Semin Surg Oncol. 1995;11:240–245
  47. Casselman JW, Mancuso AA. Major salivary gland masses: comparison of MR imaging and CT. Radiology. 1987;165:183–189
  48. Byrne MN, Spector JG, Garvin CF, Gado MH. Preoperative assessment of parotid masses: a comparative evaluation of radiologic techniques to histopathologic diagnosis. Laryngoscope. 1989;99:284–292
  49. Weber AL. Imaging of the salivary glands. Curr Opin Radiol. 1992;4:117–122
  50. Renehan A, Gleave EN, Hancock BD, Smith P, McGurk M. Long-term follow-up of over 1000 patients with salivary gland tumours treated in a single centre. Br J Surg. 1996;83:1750–1754
  51. Gal R. Fine needle aspiration of the salivary glands: a review. Oper Tech Otolaryngol Head Neck Surg. 1996;7:323–326
  52. Riley N, Allison R, Stevenson S. Fine-needle aspiration cytology in parotid masses: our experience in Canterbury, New Zealand. ANZ J Surg. 2005;75:144–146
  53. Ellis GL, Auclair PL. Tumors of the salivary glands, atlas of tumor pathology, 3rd series, fascicle 17. Washington, DC: Armed Forces Institute of Pathology; 1996;p. 135–6
  54. Guzzo M, Ferrari A, Marcon I, et al. Salivary gland neoplasms in children: the experience of the Istituto Nazionale Tumori of Milan. Pediatr Blood Cancer. 2006;47:806–810
  55. Gnepp DR, Brandwein MS, Henley JD. Salivary and lacrimal glands. In:  Gnepp DR editors. Diagnostic surgical pathology of head and neck. Philadelphia: Saunders; 2001;p. 408
  56. UICC . UICC (International Union Against Cancer). In:  Sobin LH, Wittekind Ch  editor. TNM classification of malignant tumours. 6th ed.. New York, Chichester, Weinheim, Brisbane, Singapore, Toronto: Wiley-Liss; 2002;
  57. Cermik TF, Mavi A, Acikgoz G, et al. FDG PET in detecting primary and recurrent malignant salivary gland tumors. Clin Nucl Med. 2007;32:286–291
  58. Jackel MC, Reischl A, Huppert P. Efficacy of radiologic screening for distant metastases and second primaries in newly diagnosed patients with head and neck cancer. Laryngoscope. 2007;117:242–247
  59. Chen I, Tu H. Pleomorphic adenoma of the parotid gland metastasizing to the cervical lymph node. Otolaryngol Head Neck Surg. 2000;122:455–457
  60. Castle JT, Thompson LD, Frommelt RA, Wenig BM, Kessler HP. Polymorphous low grade adenocarcinoma: a clinicopathologic study of 164 cases. Cancer. 1999;86:207–219
  61. Evans HL, Luna MA. Polymorphous low-grade adenocarcinoma: a study of 40 cases with long-term follow up and an evaluation of the importance of papillary areas. Am J Surg Pathol. 2000;24:1319–1328
  62. Witt RL. Major salivary gland cancer. Surg Oncol Clin N Am. 2004;13:113–127
  63. Hickman RE, Cawson RA, Duffy SW. The prognosis of specific types of salivary gland tumors. Cancer. 1984;54:1620–1624
  64. Guzzo M, Andreola S, Sirizzotti G, Cantu G. Mucoepidermoid carcinoma of the salivary glands: clinicopathologic review of 108 patients treated at the National Cancer Institute of Milan. Ann Surg Oncol. 2002;9:688–695
  65. Clode AL, Fonseca I, Santos JR, Soares J. Mucoepidermoid carcinoma of the salivary glands: a reappraisal of the influence of tumor differentiation on prognosis. J Surg Oncol. 1991;46:100–106
  66. Nagao T, Sugano I, Ishida Y, et al. Salivary gland malignant myoepithelioma: a clinicopathologic and immunohistochemical study of ten cases. Cancer. 1998;83:1292–1299
  67. Di Palma S, Guzzo M. Malignant myoepithelioma of salivary glands: clinicopathological features of ten cases. Virchows Arch A Pathol Anat Histopathol. 1993;423:389–396
  68. Hamper K, Lazar F, Dietel M, et al. Prognostic factors for adenoid cystic carcinoma of the head and neck: a retrospective evaluation of 96 cases. J Oral Pathol Med. 1990;19:101–107
  69. Perzin KH, Gullane P, Clairmont AC. Adenoid cystic carcinomas arising in salivary glands: a correlation of histologic features and clinical course. Cancer. 1978;42:265–282
  70. Tortoledo ME, Luna MA, Batsakis JG. Carcinomas ex pleomorphic adenoma and malignant mixed tumors. Histomorphologic indexes. Arch Otolaryngol. 1984;110:172–176
  71. Lewis JE, Olsen KD, Sebo TJ. Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol. 2001;32:596–604
  72. Guzzo M, Di Palma S, Grandi C, Molinari R. Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck. 1997;19:126–133
  73. Barnes L, Rao U, Krause J, et al. Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol. 1994;78:64–73
  74. Bhattacharyya N, Fried MP. Nodal metastasis in major salivary gland cancer: predictive factors and effects on survival. Arch Otolaryngol Head Neck Surg. 2002;128:904–908
  75. Frankenthaler RA, Luna MA, Lee SS, et al. Prognostic variables in parotid gland cancer. Arch Otolaryngol-Head Neck Surg. 1991;117:1251–1256
  76. Spiro RH, Huvos AG. Stage means more than grade in adenoid cystic carcinoma. Am J Surg. 1992;164:623–628
  77. Carrillo JF, Vazquez R, Ramirez-Ortega MC, et al. Multivariate prediction of the probability of recurrence in patients with carcinoma of the parotid gland. Cancer. 2007;109:2043–2051
  78. Chen AM, Garcia J, Lee NY, Bucci MK, Eisele DW. Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: what is the role of elective neck irradiation?. Int J Radiat Oncol Biol Phys. 2007;67:988–994
  79. Fordice J, Kershaw C, El-Naggar A, Goepfert H. Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg. 1999;125:149–152
  80. Triantafillidou K, Dimitrakopoulos J, Iordanidis F, Koufogiannis D. Management of adenoid cystic carcinoma of minor salivary glands. J Oral Maxillofac Surg. 2006;64:1114–1120
  81. Seethala RR, Barnes EL, Hunt JL. Epithelial–myoepithelial carcinoma: a review of the clinicopathologic spectrum and immunophenotypic characteristics in 61 tumors of the salivary glands and upper aerodigestive tract. Am J Surg Pathol. 2007;31:44–57
  82. Strick MJ, Kelly C, Soames JV, McLean NR. Malignant tumours of the minor salivary glands—a 20 year review. Br J Plast Surg. 2004;57:624–631
  83. Roh JL, Kim HS, Park CI. Randomized clinical trial comparing partial parotidectomy versus superficial or total parotidectomy. Br J Surg. 2007;94:1081–1087
  84. Leverstein H, van der Wal JE, Tiwari RM, van dW I, Snow GB. Surgical management of 246 previously untreated pleomorphic adenomas of the parotid gland. Br J Surg. 1997;84:399–403
  85. Weber RS, Byers RM, Petit B, et al. Submandibular gland tumors. Adverse histologic factors and therapeutic implications. Arch Otolaryngol Head Neck Surg. 1990;116:1055–1060
  86. Stennert E, Kisner D, Jungehuelsing M, et al. High incidence of lymph node metastasis in major salivary gland cancer. Arch Otolaryngol Head Neck Surg. 2003;129:720–723
  87. Scianna JM, Petruzzelli GJ. Contemporary management of tumors of the salivary glands. Curr Oncol Rep. 2007;9:134–138
  88. Bell RB, Dierks EJ, Homer L, Potter BE. Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg. 2005;63:917–928
  89. Armstrong JG, Harrison LB, Thaler HT, et al. The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer. 1992;69:615–619
  90. Ferlito A, Shaha AR, Rinaldo A, Mondin V. Management of clinically negative cervical lymph nodes in patients with malignant neoplasms of the parotid gland. ORL J Otorhinolaryngol Relat Spec. 2001;63:123–126
  91. Ferlito A, Shaha AR, Rinaldo A. Surgical management of head and neck cancer: the next decade. Acta Otolaryngol. 2001;121:772–776
  92. Gavilan C, Gavilan J. Five-year results of functional neck dissection for cancer of the larynx. Arch Otolaryngol Head Neck Surg. 1989;115:1193–1196
  93. Lingeman RE, Helmus C, Stephens R, Ulm J. Neck dissection: radical or conservative. Ann Otol Rhinol Laryngol. 1977;86:737–744
  94. Molinari R, Cantu G, Chiesa F, Grandi C. Retrospective comparison of conservative and radical neck dissection in laryngeal cancer. Ann Otol Rhinol Laryngol. 1980;89:578–581
  95. Borthne A, Kjellevold K, Kaalhus O, Vermund H. Salivary gland malignant neoplasms: treatment and prognosis. Int J Radiat Oncol Biol Phys. 1986;12:747–754
  96. Elkon D, Colman M, Hendrickson FR. Radiation therapy in the treatment of malignant salivary gland tumors. Cancer. 1978;41:502–506
  97. Fitzpatrick PJ, Theriault C. Malignant salivary gland tumors. Int J Radiat Oncol Biol Phys. 1986;12:1743–1747
  98. Harrison LB, Armstrong JG, Spiro RH, Fass DE, Strong EW. Postoperative radiation therapy for major salivary gland malignancies. J Surg Oncol. 1990;45:52–55
  99. McNaney D, McNeese MD, Guillamondegui OM, Fletcher GH, Oswald MJ. Postoperative irradiation in malignant epithelial tumors of the parotid. Int J Radiat Oncol Biol Phys. 1983;9:1289–1295
  100. North CA, Lee DJ, Piantadosi S, Zahurak M, Johns ME. Carcinoma of the major salivary glands treated by surgery or surgery plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 1990;18:1319–1326
  101. Catterall M, Errington RD. The implications of improved treatment of malignant salivary gland tumors by fast neutron radiotherapy. Int J Radiat Oncol Biol Phys. 1987;13:1313–1318
  102. Douglas JG, Laramore GE, Austin-Seymour M, et al. Neutron radiotherapy for adenoid cystic carcinoma of minor salivary glands. Int J Radiat Oncol Biol Phys. 1996;36:87–93
  103. Garden AS, Weber RS, Ang KK, et al. Postoperative radiation therapy for malignant tumors of minor salivary glands, outcome and patterns of failure. Cancer. 1994;73:2563–2569
  104. Garden AS, El-Naggar AK, Morrison WH, et al. Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Biol Phys. 1997;37:79–85
  105. Griffin BR, Laramore GE, Russell KJ, Griffin TW, Eenmaa J. Fast neutron radiotherapy for advanced malignant salivary gland tumors. Radiother Oncol. 1988;12:105–111
  106. Griffin TW, Pajak TF, Laramore GE, et al. Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC cooperative randomized study. Int J Radiat Oncol Biol Phys. 1988;15:1085–1090
  107. Krull A, Schwarz R, Heyer D, Timm H, Schmidt R. Results of neutron therapy in recurrent malignant salivary gland tumors in the head and neck area. Strahlenther Onkol. 1995;171:265–271
  108. Saroja KR, Mansell J, Hendrickson FR, Cohen L, Lennox A. An update on malignant salivary gland tumors treated with neutrons at Fermilab. Int J Radiat Oncol Biol Phys. 1987;13:1319–1325
  109. Sessions RB, Lehane DE, Smith RJ, Bryan RN, Suen JY. Intra-arterial cisplatin treatment of adenoid cystic carcinoma. Arch Otolaryngol. 1982;108:221–224
  110. Stelzer KJ, Laramore GE, Griffin TW, et al. Fast neutron radiotherapy. The University of Washington experience. Acta Oncol. 1994;33:275–280
  111. Terhaard CH, Lubsen H, Van dT I, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck. 2004;26:681–692
  112. Radiation Therapy Oncology Group. Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Medical Research Council. Int J Radiat Oncol Biol Phys. 1993;27:235–240
  113. Douglas JG, Koh WJ, Austin-Seymour M, Laramore GE. Treatment of salivary gland neoplasms with fast neutron radiotherapy. Arch Otolaryngol Head Neck Surg. 2003;129:944–948
  114. Bittner N, Koh WJ, Laramore GE, et al. Treatment of locally advanced adenoid cystic carcinoma of the trachea with neutron radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:410–414
  115. Schulz-Ertner D, Nikoghosyan A, Didinger B, et al. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer. 2005;104:338–344
  116. Barnett TA, Kapp DS, Goffinet DR. Adenoid cystic carcinoma of the salivary glands. Management of recurrent, advanced, or persistent disease with hyperthermia and radiation therapy. Cancer. 1990;65:2648–2656
  117. Gabriele P, Amichetti M, Orecchia R, Valdagni R. Hyperthermia and radiation therapy for inoperable or recurrent parotid carcinoma. A phase I/II study. Cancer. 1995;75:908–913
  118. Locati LD, Guzzo M, Bossi P, et al. Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. Oral Oncol. 2005;41:890–894
  119. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006;24:2673–2678
  120. Airoldi M, Brando V, Giordano C, et al. Chemotherapy for recurrent salivary gland malignancies: experience of the ENT Department of Turin University. ORL J Oto-Rhino-Laryngol Relat Spec. 1994;56:105–111
  121. Alberts DS, Manning MR, Coulthard SW, Koopmann CFJ, Herman TS. Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer. 1981;47:645–648
  122. Belani CP, Eisenberger MA, Gray WC. Preliminary experience with chemotherapy in advanced salivary gland neoplasms. Med Pediatr Oncol. 1988;16:197–202
  123. Creagan ET, Woods JE, Rubin J, Schaid DJ. Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer. 1988;62:2313–2319
  124. Dimery IW, Legha SS, Shirinian M, Hong WK. Fluorouracil, doxorubicin, cyclophosphamide, and cysplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol. 1990;8:1056–1062
  125. Jones AS, Phillips DE, Cook JA, Helliwell TR. A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands. Br J Cancer. 1993;67:112–114
  126. Licitra L, Marchini S, Spinazze S, et al. Cisplatin in advanced salivary gland carcinoma. A phase II sudy of 25 patients. Cancer. 1991;68:1874–1877
  127. Licitra L, Cavina R, Grandi C, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol. 1996;7:640–642
  128. Posner MR, Ervin TJ, Weichselbaum RR, Fabian RL, Miller D. Chemotherapy of advanced salivary gland neoplasms. Cancer. 1982;50:2261–2264
  129. Schramm VLJ, Srodes C, Myers EN. Cisplatin therapy for adenoid cystic carcinoma. Arch Otolaryngol. 1981;107:739–741
  130. Triozzi PL, Brantley A, Fisher S, et al. 5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck. Cancer. 1987;59:887–890
  131. Venook AP, Tseng AJ, Meyers FJ, et al. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol. 1987;5:951–955
  132. Kaplan MJ, Johns ME, Cantrell RW. Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg. 1986;95:165–170
  133. Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck. 2006;28:197–204
  134. van Herpen CM, Locati LD, Buter J, et al. Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). Eur J Cancer. 2008;44:2542–2545
  135. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol. 2005;23:585–590
  136. Glisson BS, Blumenschein G, Francisco M, et al. Phase II trial of gefitinib in patients with incurable salivary gland cancer. In: ASCO Annual Meeting Proceedings, vol. 23. 2005;p. 508s
  137. Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol. 2009;45:574–578
  138. Agulnik M, Cohen EW, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007;25:3978–3984
  139. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003;39:724–727
  140. Alcedo JC, Fabrega JM, Arosemena JR, Urrutia A. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck. 2004;26:829–831
  141. Faivre S, Raymond E, Casiraghi O, Temam S, Berthaud P. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol. 2005;23:6271–6273
  142. Argiris A, Goldwasser MA, Burtness B, et al. A phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: An Eastern Cooperative Oncology Group study. ASCO Annual Meeting Proceedings Part I, vol. 24, no. 18S (June 20 Supplement). J Clin Oncol. 2006;5573
  143. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;23:5474–5483
  144. Helmus C. Subtotal parotidectomy: a 10-year review (1985–1994). Laryngoscope. 1997;107:1024–1027
  145. Stevens KL, Hobsley M. The treatment of pleomorphic adenomas by formal parotidectomy. Br J Surg. 1982;69:1–3
  146. Myssiorek D, Ruah CB, Hybels RL. Recurrent pleomorphic adenomas of the parotid gland. Head Neck. 1990;12:332–336
  147. Simpson JR. Cancer of the salivary glands. In:  Perez CA,  Brady LW editor. Radiation oncology. Philadelphia: Lippincott; 1987;p. 513–528
  148. McNeese MD, Fletcher GH. Tumors of the major and minor salivary glands. Radiation therapy of head and neck cancer. Berlin, Heidelberg, New York, London, Pris, Tokyo: Springer–Verlag; 1989;p. 181–96
  149. Moss WT. The salivary glands. Moss’ radiation oncology: rationale, technique, results. 7th ed.. Mosby; 1994;p. 121–31

PII: S1040-8428(09)00217-0

doi: 10.1016/j.critrevonc.2009.10.004

Critical Reviews in Oncology / Hematology
Volume 74, Issue 2 , Pages 134-148 , May 2010

Article Tools

* Image Usage & Resolution